<!DOCTYPE html>
<html>
<head>
<title>Flucelvax Tetra INN-Influenza vaccine (surface antigen inactivated prepared in cell cultures);</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:86pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product is subject to additional monitoring. This will allow quick identification of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">new safety information. Healthcare professionals are asked to report any suspected adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">See section 4.8 for how to report adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra - suspension for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">strains*: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A/Wisconsin/588/2019 (H1N1)pdm09-like strain (A/Delaware/55/2019 CVR-45) 15 micrograms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HA** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type) 15 micrograms HA** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) 15 micrograms HA** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type) 15 micrograms HA** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">per 0.5 ml dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">propagated in Madin Darby Canine Kidney (MDCK) cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">haemagglutinin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The vaccine complies with the World Health Organisation (WHO) recommendation (northern </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hemisphere) and EU recommendation for the 2022/2023 SEASON. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra may contain traces of beta-propiolactone, cetyltrimethylammonium bromide, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polysorbate 80.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL </span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">FORM</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suspension for injection in pre-filled syringe (injection). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clear to slightly opalescent liquid. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> PARTICULARS</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Prophylaxis of influenza in adults and children from 2 years of age.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra should be used in accordance with official recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adults and children from 2 years of age: </span></p>
<img style="position:absolute;top:56pt;left:70pt;width:15pt;height:13pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAADAAAAAqCAYAAAD1T9h6AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAARUlEQVR4nO3PAQ0AIAAEobd/aI1xc4MGnG13HzsTaAnUBGoCNYGa
QE2gJlATqAnUBGoCNYGaQE2gJlATqAnUBGoCte8DD2cqKgG1q7tIAAAAAElFTkSu
QmCC">
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Age Group </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:220pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:363pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Schedule </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 to &lt; 9 years</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:220pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One or two</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 0.5 mL doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If 2 doses, administer at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 weeks apart</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9 years of age and older</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:220pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One 0.5 mL dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> Children less than 9 years of age who have not been previously vaccinated against influenza, should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive a second dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Flucelvax Tetra in children from birth to less than 2 years of age has not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been established. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For intramuscular injection only.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The preferred site for injection is the deltoid muscle of the upper arm. Young children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insufficient deltoid mass should be vaccinated in the anterolateral aspect of the thigh.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The vaccine must not be injected intravenously, subcutaneously or intradermally and must not be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mixed with other vaccines in the same syringe. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For instructions on the handling of the vaccine before administration, see section 6.6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to possible </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trace residues such as beta-propiolactone, cetyltrimethylammonium bromide, and polysorbate 80. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the name and the batch number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the administered product should be clearly recorded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Appropriate medical treatment and supervision should always be readily available in case of a rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic event following the administration of the vaccine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccination should be postponed in patients with acute febrile illness until the fever is resolved.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with all injectable vaccines, Flucelvax Tetra must be administered with caution to individuals with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the needle injection. This can be accompanied by several neurological signs such as transient visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">procedures are in place to avoid injury from faints. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to prevent influenza. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A protective immune response may not be elicited in all vaccine recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interaction studies have been performed with Flucelvax Tetra. There are no data available on co-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of Flucelvax Tetra with other vaccines. Based on clinical experience with cell-based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trivalent influenza vaccine (TIVc), Flucelvax Tetra can be given at the same time as other vaccines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Inactivated influenza vaccines, such as Flucelvax Tetra, can be given in any stage of pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Larger safety datasets are available on vaccine use during the second or third trimester, compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first trimester; however, data from worldwide use of influenza vaccines do not indicate any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse foetal and maternal outcomes attributable to the vaccine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A prospective Pregnancy Exposure Registry was conducted in the United States (US) and data were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">collected from 665 women vaccinated with Flucelvax Tetra during 3 Northern Hemisphere influenza </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seasons (2017-18 to 2019-20), of whom 28% were exposed during their first trimester. Based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy outcomes and predefined infant safety outcomes, there was no evidence of adverse foetal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">newborn or pregnancy outcomes attributable to the vaccine during any stage of pregnancy.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been no reproductive and developmental toxicology studies with Flucelvax Tetra. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive and developmental toxicology data from cell-based trivalent influenza vaccine (TIVc) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">do not predict an increased risk of developmental abnormalities. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether Flucelvax Tetra is excreted in human milk. No effects on breast fed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">newborn/infant are anticipated. Flucelvax Tetra may be given during lactation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No human fertility data are available. Animal data, with cell-based trivalent influenza vaccine (TIVc), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not shown effects on female fertility. Male fertility has not been assessed in animals. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra has no or negligible influence on the ability to drive and use machines.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Summary of the safety profile </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety of Flucelvax Tetra in adults 18 years and older was evaluated in a randomised, controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study (V130_01), in which 1334 subjects received Flucelvax Tetra. Similar rates of solicited local and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">systemic adverse reactions were reported in subjects who received Flucelvax Tetra and cell-based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trivalent influenza vaccine comparator in this clinical trial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most commonly reported (&#x2265;10%) reactions in subjects who received Flucelvax Tetra were pain at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the injection site (34%), headache (14%), fatigue (14%), myalgia (14%), erythema (13%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">induration (10%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of some adverse reactions </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were considerably lower among subjects &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years of age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when compared to subjects 18 to &lt; 65 years of age (see table below).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions reported are listed according to the following frequency categories: Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;1/10); Common (&#x2265;1/100</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1/10); Uncommon (&#x2265;1/1,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to &lt;1/100), not known (cannot be estimated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from the available data). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1:  Adverse reactions reported following vaccination in adults 18 years and older in </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">clinical trials and post-marketing surveilance. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">MedDRA System Organ class</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:222pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Very common</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:237pt"><span style="font-family:SymbolMT,sans-serif;font-size:9.96pt">(&#xf0b3;</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1/10)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:317pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Common</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(</span><span style="font-family:SymbolMT,sans-serif;font-size:9.96pt">&#xf0b3;</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1/100 to &lt;1/10)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:398pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Uncommon</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:397pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(</span><span style="font-family:SymbolMT,sans-serif;font-size:9.96pt">&#xf0b3;</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:406pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&lt;1/100)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:489pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Frequency  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:487pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">not known</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">3 </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Immune system disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Allergic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">immediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">reactions, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">anaphylactic shock</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Metabolism and nutrition </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Loss of appetite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:470pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Nervous system disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Headache</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Paraesthesia,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Guillain-Barre </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Syndrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Gastrointestinal disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:215pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Nausea,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Diarrhoea,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Vomiting</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:470pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Skin and subcutaneous tissue </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:215pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Generalised skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">reactions including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">pruritus, urticaria or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">non-specific rash </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Musculoskeletal and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">connective tissue disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Myalgia</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Arthralgia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:385pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:470pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">General disorders and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">administration site conditions </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injection site pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Fatigue</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Induration</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ecchymosis,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Chills </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Fever </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 38</span><span style="font-family:SymbolMT,sans-serif;font-size:9.96pt">&#xf0b0;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Extensive swelling </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">of injected limb   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Reported as Common in the elderly population 65 years of age and older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Reported as Uncommon in the elderly population 65 years of age and older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Adverse reactions reported from post-marketing surveillance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population (2 to less than 18 years of age)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety of Flucelvax Tetra in children 2 to less than 18 years of age has been evaluated in two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical studies, V130_03 and V130_12. In the randomised, controlled study V130_03,  1159 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paediatric subjects received Flucelvax Tetra (584 subjects 9 to &lt;18 years; 575 subjects 4 to &lt;9 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Children 9 to less than 18 years of age received a single dose of Flucelvax Tetra. Children 4 to less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than 9 years of age received one or two doses (separated by 4 weeks) of Flucelvax Tetra based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">deter</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mination of the subject&#x2019;s prior influenza vaccination history. In this age group, 235 paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects received one dose and 340 subjects received two doses. Similar rates of solicited local and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">systemic adverse reactions were reported in subjects who received Flucelvax Tetra and cell-based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trivalent influenza vaccine comparator in this clinical trial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the multinational, randomised, observer-blind study V130_12, the safety population included a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of 2255 children 2 to less than 18 years of age who received Flucelvax Tetra (580 subjects 2 to &lt; 6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">years; 564 subjects 6 to &lt; 9 years; 1111 subjects 9 to &lt; 18 years). Children 9 to less than 18 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age received a single dose of Flucelvax Tetra. Children 2 to less than 9 years of age received one or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">two doses (separated by 28 days) of Flucelvax Tetra based on determination of the subject&#x2019;s prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">influenza vaccination history. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most common local and systemic adverse reactions reported in either study is described below by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paediatric sub-group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">T</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">he most common (&#x2265;10%) </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">local and systemic adverse reactions after one dose reported in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects of 9 to &lt; 18 years of age were injection site pain (58%), headache (22%), erythema (19%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue (18%), myalgia (16%), and induration (15%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">T</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">he most common (&#x2265;10%) local and systemic </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions after any vaccination in children 6 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">less than 9 years of age were pain at the injection site (61%), injection site erythema (25%), injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">site induration (19%), fatigue (16%), headache (16%) and injection site ecchymosis (11%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most common (&#x2265;10%) local and systemic adverse reactions after any vaccination in children 2 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">less than 6 years of age were tenderness at the injection site (54%), injection site erythema (23%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sleepiness (21%), irritability (19%), injection site induration (15%), change in eating habits (14%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injection site ecchymosis (11%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Compared to adults 18 years of age and older, paediatric subjects generally reported higher rates of local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and systemic adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In children who received a second dose of Flucelvax Tetra the incidence of adverse reactions following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the second dose of vaccine was similar or slightly lower to that observed with the first dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions in children 2 to less and 18 years of age in these clinical studies are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">described in Table 2 below. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12pt">Table 2: Solicited adverse reactions reported in clinical studies in children 2 to &lt; 18 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12pt">years of age </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:87pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">MedDRA System </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Organ class</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:104pt;left:197pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Adverse Reactions </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:384pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:407pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:237pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:340pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">2 to &lt; 9 years</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:447pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">9 to &lt; 18 years</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:314pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">2 to &lt; 6 </span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">1</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:389pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">6 to &lt;9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:89pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Metabolism and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:83pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">nutrition disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:205pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Loss of appetite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Nervous system </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:104pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:89pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Gastrointestinal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:104pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Diarrhoea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:222pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:218pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:80pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Musculoskeletal and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:88pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">connective tissue </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:104pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Myalgia </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:323pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Arthralgia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:85pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">General disorders </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:83pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">and administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:93pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">site conditions </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injection site tenderness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:395pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:201pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injection site pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:191pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injection site erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:187pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injections site induration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:187pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Injection site ecchymosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:374pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sleepiness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:395pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Irritability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:395pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:222pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:190pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Change in eating habits </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:395pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:204pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Chills/Shivering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:207pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Fever (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">38&#xb0; C) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:385pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">The youngest age range in study V130_03 was 4 to &lt; 6 years </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Myalgia reported with a frequency of Common (3% and 6%) in children 6 to &lt; 9 and 9 to &lt; 18 years, respectively, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">in study V130_12   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no data for overdose with Flucelvax Tetra. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra provides active immunisation against four influenza virus strains (two A subtypes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">two B types) contained in the vaccine. Flucelvax Tetra induces humoral antibodies against the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">haemagglutinins. These antibodies neutralise influenza viruses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra is manufactured using Madin Darby Canine Kidney (MDCK) cells. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Specific levels of haemagglutination inhibition (HI) antibody titres post-vaccination with inactivated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">influenza vaccine have not been correlated with protection from influenza virus. In some human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies, antibody titres of 1:40 or greater have been associated with protection from influenza illness in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">up to 50% of subjects. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibody against one influenza virus type or subtype confers limited or no protection against another. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antigenic variant of the same type or subtype.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Annual revaccination with current influenza vaccines is recommended because immunity declines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the year after vaccination and circulating strains of influenza virus may change from year to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity of Flucelvax Tetra</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in Adults 18 years of age and older </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immunogenicity of Flucelvax Tetra was evaluated in adults 18 years of age and older in a randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind, controlled study (V130_01). In this study, subjects received Flucelvax Tetra (N = 1334) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or one of the two formulations of comparator cell-based trivalent influenza vaccine (TIVc) [TIV1c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(N = 677) or TIV2c (N = 669)]. The immune response to each of the vaccine antigens was assessed, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">21 days after vaccination. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The immunogenicity endpoints were geometric mean antibody titres (GMTs) of haemagglutination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibition (HI) antibodies response and percentage of subjects who achieved seroconversions, defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">as a pre-vaccination HI titre of &lt;1:10 with a post vaccination titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;1:40 or with a pre</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-vaccination HI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titre of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 and a minimum 4-fold increase in serum HI antibody titre. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra was non-inferior to TIVc. Non-inferiority was established for all 4 influenza strains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">included in Flucelvax Tetra, as assessed by ratios of GMTs and the differences in the percentages of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects achieving seroconversion at 3 weeks following vaccination. The antibody response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">influenza B strains contained in Flucelvax Tetra was superior to the antibody response after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccination with TIVc containing an influenza B strain from the alternate lineage. There was no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evidence that the addition of the second influenza B strain resulted in immune interference to other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">strains included in the vaccine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Age subgroup analyses in subjects 18 to less than 65 years of age and 65 years of age and above </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confirmed that HI antibody responses (GMT and differences in vaccine group seroconversion rates) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">met non-inferiority immunogenicity criteria 3 weeks following vaccination for all 4 influenza strains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in both age groups. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The non-inferiority data observed are summarised in Table 3. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3:  Noninferiority of Flucelvax Tetra relative to TIVc in adults 18 years of age and above </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2013;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> Per protocol analysis set (V130_01) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:142pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:194pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Flucelvax Tetra </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:209pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N = 1250 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">TIV1c/TIV2c</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N = 635/N = 639 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:368pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Vaccine Group </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:389pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Ratio </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:470pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Vaccine </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:473pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Group </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:465pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Difference </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:467pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:75pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:87pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">H</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:111pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:122pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:131pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">GMT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:124pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">302.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(281.8-325.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">298.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(270.3-330.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:394pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:383pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.9-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.1</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:111pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Seroconversion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:112pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rate</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">49.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:205pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(46.4-52.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">48.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(44.7-52.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:61pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:475pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-0.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:468pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-5.3-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">4.2</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H3N2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:131pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">GMT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:124pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">372.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(349.2-396.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:299pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">378.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(345.1-414.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:394pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:383pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.9-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.1</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:111pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Seroconversion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:112pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rate</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">38.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:205pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(35.6-41.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">35.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(31.9-39.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:475pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-2.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:468pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-7.2-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.9</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:131pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">GMT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:124pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">133.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(125.3-141.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:299pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">115.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(106.4-125.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:394pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:383pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.8-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.0</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:111pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Seroconversion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:112pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rate</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">36.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:205pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(33.9-39.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">34.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(31.1-38.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:475pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-1.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:468pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-6.2-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">2.8</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:131pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">GMT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:124pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">177.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(167.6-187.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:299pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">164.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(151.4-177.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:394pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:383pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.9-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.0</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:111pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Seroconversion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:112pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rate</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:215pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">39.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:205pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(37.0-42.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">35.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(31.7-39.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:475pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-4.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:468pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-8.9-</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">0.2</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Abbreviations: GMT = geometric mean titre; CI = confidence interval.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> The comparator vaccine for noninferiority comparisons for A/H1N1, A/H3N2 and B1 is TIV1c, for B2 it is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">TIV2c. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Seroconversion rate = percentage of subjects with either a pre-vaccination HI titre &lt;1:10 and post-vaccination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HI titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;1:40 or with a pre</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-vaccination HI titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;1:10 and a minimum 4</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-fold increase in post-vaccination HI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">antibody titre. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Bold</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> = Non-inferiority criterion met. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Clinical efficacy of cell-based trivalent influenza vaccine (TIVc) against culture-confirmed influenza </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in adults </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy experience with TIVc is relevant to Flucelvax Tetra because both vaccines are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">manufactured using the same process and have overlapping compositions.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A multinational, randomised, observer-blinded, placebo-controlled trial (V58P13) was performed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">assess clinical efficacy and safety of TIVc during the 2007-2008 influenza season in adults aged 18 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">less than 50 years. A total of 11,404 subjects were enrolled to receive TIVc (N = 3828), Agrippal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(N = 3676) or placebo (N = 3900) in a 1:1:1 ratio.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">TIVc efficacy was defined as the prevention of culture-confirmed symptomatic influenza illness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">caused by viruses antigenically matched to those in the vaccine compared to placebo. Influenza cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were identified by active and passive surveillance of influenza-like illness (ILI). ILI was defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">according to Centers for Disease Control and Prevention (CDC) case definition, i.e., a fever (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">temperature </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2265;</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100.0&#xb0;F / 38&#xb0;C) and cough or sore throat. After an episode of ILI, nose and throat swab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">samples were collected for analysis. Vaccine efficacies against vaccine-matched influenza viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">strains, against all influenza viral strains, and against individual influenza viral subtypes were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">calculated (Table 4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4:  Comparative efficacy of TIVc versus placebo against culture-confirmed influenza by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">influenza viral subtype (V58P13) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:227pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">TIVc </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:215pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(N = 3776) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:354pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:348pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(N = 3843) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:451pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Vaccine Efficacy</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">*</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:178pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Attack Rate </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:195pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(%) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:247pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Number of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:241pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Subjects with </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:250pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Influenza </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Attack Rate </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:328pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(%) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Number of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:374pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Subjects with </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:383pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Influenza </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:453pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:482pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Lower Limit </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:493pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">of One-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:482pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Sided 97.5% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:504pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">CI </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Antigenically Matched Strains </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Overall </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:195pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">0.19 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:268pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:328pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.14 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:398pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">44 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:449pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">83.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:501pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">61.0 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Individual </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">strains </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H3N2</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">**</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.05  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:334pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:506pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H1N1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:398pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">43 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">88.2</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">67.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">**</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:201pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.03 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:506pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">All Culture-Confirmed Influenza </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Overall </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:195pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">1.11 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:265pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">42 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:328pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">3.64 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:395pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">140 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:449pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">69.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:501pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">55.0 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Individual </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:88pt;left:74pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">strains </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H3N2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:398pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">75.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">35.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H1N1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:398pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">57 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">89.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">73.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.79 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:265pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.59 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:398pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">49.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">18.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">*  </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Simultaneous one-sided 97.5% confidence intervals for the vaccine efficacy of each influenza vaccine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:92pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">relative to placebo based on the Sidak-corrected score confidence intervals for the two relative risks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:92pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Vaccine Efficacy = (1 - Relative Risk) x 100%; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">**  </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">There were too few cases of influenza due to vaccine-matched influenza A/H3N2 or B to adequately assess </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:92pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">vaccine efficacy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity of Flucelvax Tetra in Children and Adolescents 4 to less than 18 Years of Age </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immunogenicity of Flucelvax Tetra was evaluated in children 4 to less than 18 years of age as part of a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised, double-blind, controlled study (V130_03). In this study, subjects received Flucelvax </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tetra (N = 1159) or one of the two formulations of comparator cell-based trivalent influenza vaccine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(TIVc) [TIV1c (N = 593), or TIV2c (N = 580)]. The immune response to each of the vaccine antigens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was assessed 21 days after vaccination. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The immunogenicity endpoints were GMTs of HI antibodies response and percentage of subjects who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">achieved seroconversions (seroconversion rate), defined as a pre-vaccination HI titre of &lt;1:10 with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">post-vaccination titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;1:40 or with a pre</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-vaccination HI titr</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">e &#x2265; 1:10 and a minimum 4</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-fold increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum HI antibody titre. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra was noninferior to TIVc in children 4 to less than 18 years of age. Non-inferiority was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">established for all 4 influenza strains included in the Flucelvax Tetra, as assessed by ratios of GMTs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and the differences in the percentages of subjects achieving seroconversion at 3 weeks following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccination. The antibody response to influenza B strains contained in Flucelvax Tetra was superior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the antibody response after vaccination with TIVc containing an influenza B strain from the alternate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lineage. There was no evidence that the addition of the second B strain resulted in immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interference to other strains included in the vaccine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The immunogenicity data in subjects 4 to less than 18 years of age are summarised in Table 5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5:  GMTs and seroconversion rates (with 95% CI) in subjects 4 to &lt;18 years of age, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 weeks after vaccination with Flucelvax Tetra or TIV1c/TIV2c - Per Protocol Set </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(V130_03) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:71pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:163pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:264pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Flucelvax Tetra </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:409pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">TIV1c/TIV2c</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">a</span></b></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H1N1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:163pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:278pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 1014 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 510 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:129pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">GMT (95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1090 (1027-1157) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:403pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1125 (1034-1224) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:117pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Seroconversion Rate</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:271pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">72%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (69-75) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:413pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">75%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (70-78) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">A/H3N2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:163pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:278pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 1013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 510 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:129pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">GMT (95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:269pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">738 (703-774) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">776 (725-831) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:117pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Seroconversion Rate</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:271pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">47%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (44-50) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:413pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">51%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (46-55) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:163pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:278pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 1013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 510 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:129pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">GMT (95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:269pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">155 (146-165) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">154 (141-168) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:117pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Seroconversion Rate</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:271pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">66%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (63-69) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:413pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">66%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (62-70) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:163pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:278pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 1009 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = 501 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:129pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">GMT (95% CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:269pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">185 (171-200) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">185 (166-207) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:117pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Seroconversion Rate</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:271pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">73%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (70-76) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:413pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">71%</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> (67-75) </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> For H1N1, H3N2 and B1 influenza strains TIV1c data are presented, whereas for B2 influenza strain TIV2c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">data are presented. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:78pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> Seroconversion rate = percentage of subjects with either a pre-vaccination HI titre &lt;1:10 and post-vaccination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HI titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;1:40 or </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">with a pre-vaccination HI titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;1:10 and a minimum 4</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-fold increase in post-vaccination HI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">antibody titre. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Bold</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- CHMP immunogenicity criteria met. The percentage of subjects with seroconversion or significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">increase in HI antibody titre is &gt;40%, the percentage of subjects achieving an HI titre </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;1:40 is &gt;70%.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Clinical efficacy of Flucelvax Tetra in the paediatric population 2 to less than 18 years of age </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absolute efficacy of Flucelvax Tetra was evaluated in children 2 to less than 18 years of age in Study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">V130_12. This was a multinational, randomised, non-influenza vaccine comparator-controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">efficacy study conducted in 8 countries over 3 influenza seasons, in which 4514 subjects were enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to received 0.5 ml of Flucelvax Tetra or a non-influenza comparator in a 1:1 ratio. Based on influenza </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccination history, participants received one or two doses (28 days apart) of the study vaccine.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">efficacy was assessed by the prevention of confirmed influenza illness caused by any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">influenza Type A or B strain.  Influenza cases were identified by active surveillance of influenza-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">illness (ILI) and confirmed by viral culture and/or real-time polymerase chain reaction (RT-PCR).  An </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ILI episode was defined as a fever body </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">temperature &#x2265; 37.8&#xb0;C) along with </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at least one of the following: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough, sore throat, nasal congestion, or rhinorrhoea. Vaccine efficacy against laboratory confirmed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">influenza was calculated (Table 6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 6: Number of Subjects with First-Occurrence RT-PCR Confirmed or Culture Confirmed </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Influenza and Absolute Vaccine Efficacy (95% CI), in Subjects 2 to less than 18 Years </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:121pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">of Age</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2013;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> FAS Efficacy</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">1</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> (Study V130_12) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:202pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Number </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:197pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">of subjects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:212pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">per </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:200pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">protocol</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">1</span></b></sup><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt"> </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:258pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Number </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:254pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">of cases of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:256pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">influenza</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:315pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Attack </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:319pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Rate</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:321pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(%)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:382pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Vaccine Efficacy (VE)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt"> </span></b></sup><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt"> </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:381pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">%</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:430pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">95% CI of VE</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt"> </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">RT-PCR or Culture Confirmed Influenza</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2257 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">175 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:323pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">7.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">54.63 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:436pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">45.67, 62.12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Non-Influenza Comparator </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2252 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">364 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:320pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">16.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:384pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Culture Confirmed Influenza</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2257 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">115 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:323pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">5.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">60.81 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:436pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">51.30, 68.46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Non-Influenza Comparator </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2252 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">279 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:320pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">12.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:384pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Antigenically Matched Culture-Confirmed Influenza</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flucelvax Tetra</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2257 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:271pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:323pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">4.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">63.64 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:436pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">53.64, 71.48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Non-Influenza Comparator </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:209pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2252 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">236 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:320pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:384pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Number of subjects in the Full-Analysis Set (FAS)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">&#x2013;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> Efficacy, which included all subjects randomised, received a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">study vaccination and provided efficacy data. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity and toxicity to reproduction and development.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium chloride </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium chloride </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium chloride hexahydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Disodium phosphate dihydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium dihydrogen phosphate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Water for injections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in a refrigerator (2&#xb0;C </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2013;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 8&#xb0;C). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not freeze. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Keep the pre-filled syringe in the outer carton in order to protect from light. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 ml suspension in pre-filled syringes (type I glass), with a plunger stopper (bromobutyl rubber), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with or without needle.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pack of 1 pre-filled syringe, with or without needle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pack of 10 pre-filled syringes, with or without needles. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Shake before use. After shaking, the normal appearance of the vaccine is a clear to slightly opalescent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suspension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The vaccine should be visually inspected for particulate matter and discoloration prior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration. In the event of any foreign particulate matter and/or variation of physical aspect is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed, do not administer the vaccine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:36pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Seqirus Netherlands B.V. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paasheuvelweg 28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1105BJ Amsterdam </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Netherlands </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1326/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1326/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1326/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1326/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 12 December 2018 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:214pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
















</body>
</html> 

